Loading clinical trials...

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib | Clinical Trials | Clareo Health

COMPLETEDPHASE2

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

A PHASE 2, OPEN-LABEL, TWO ARM TRIAL TO EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS WITH ADVANCED NSCLC AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN AND FAILURE OF PRIOR TREATMENT WITH ERLOTINIB

NCT00548093•Pfizer

View on ClinicalTrials.gov

Summary

To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Advanced Non-Small Cell Lung Cancer (NSCLC)
•Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib.
•Prior treatment with no more than two chemotherapy regimens, including adjuvant or combined modality treatment.
•Measurable disease .
•Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
•Tissue available for KRAS/ EGFR testing
•Creatinine clearance \> 40 cc/min or serum creat \< 1.5 x ULN

Exclusion Criteria

•Chemotherapy
•Radiotherapy
•Biological or investigational agents within 4 weeks of baseline disease assessment.
•Patients who lack of tolerance of erlotinib therapy.

Locations (19)

City of Hope

Duarte, California, United States

City of Hope Medical Group

Pasadena, California, United States

City of Hope South Pasadena Cancer Center

South Pasadena, California, United States

Rocky Mountain Lions Eye Institute

Aurora, Colorado, United States

University of Colorado Hospital, Anschutz Cancer Pavilion

Aurora, Colorado, United States

University of Colorado Hospital, Anschutz Inpatient Pavilion

Aurora, Colorado, United States

University of Colorado Hospital

Aurora, Colorado, United States

Grady Health Systems

Atlanta, Georgia, United States

Emery University Hospital Midtown

Atlanta, Georgia, United States

Emory Clinic

Atlanta, Georgia, United States

Key Dates

Start Date

April 29, 2008

Primary Completion Date

March 16, 2010

Completion Date

June 11, 2012

Last Updated

May 21, 2019

Enrollment

ACTUAL participants

Conditions

Carcinoma, Non Small Cell Lung

Interventions

PF-00299804

DRUG

PF-00299804

DRUG

Locally Advanced NSCLC Hyperfractionated RT

NCT03128008

Carcinoma, Non Small Cell Lung (NSCLC)

View study

COMPLETEDPHASE2

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

NCT01671332

Carcinoma, Non Small Cell Lung

View study

COMPLETEDPHASE2

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

NCT00798720

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 21, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Inclusion Criteria

Exclusion Criteria

Locally Advanced NSCLC Hyperfractionated RT

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer